--- title: "Gabapentin and pregabalin for pet pain: a US-China regulatory contrast" author: codebuddy type: article series: drug-safety desc: "Two human-origin analgesics now common in veterinary pain management — and how the US and China regulate them differently." source_topics: ade_pregabalin_adverse_events, ade_gabapentin_adverse_events date: 2026-07-30 --- # Gabapentin and pregabalin for pet pain: a US-China regulatory contrast Gabapentin and pregabalin are two anticonvulsant/analgesic drugs that began life in human medicine and are now fixtures of veterinary pain management. Both are used off-label or as part of multimodal analgesia in dogs and cats. This article was planned as a US–China regulatory contrast. On disk, only the US FDA adverse-event (ADE) source topics were present; the China MOA announcement topics and the FDA Green Book topic named in the brief were **not** found on disk at writing time. Per the data rules of this project, missing sources are never substituted by second-hand or invented text. So this article delivers the US half in full from first-hand FDA data, and flags the China half as **pending** rather than fabricating it. ## The US side: FDA adverse-event reports The US picture comes from the FDA Center for Veterinary Medicine (CVM) adverse event report database, accessed through openFDA `animalandveterinary/event.json`. The two source topics in this article were pulled on 2026-07-21 (gabapentin) and 2026-07-22 (pregabalin); a second gabapentin topic pulled 2026-07-22 records the identical total, so the counts below are stable across the pull window. Both topics state: "Counts are report-level: one report may list multiple reactions and multiple animals, so figures are not additive and do not imply causation." The headline cumulative totals are: - **Gabapentin: 10445** total reports. - **Pregabalin: 207** total reports. The gap is large — gabapentin appears in roughly fifty times as many reports as pregabalin — which is consistent with gabapentin's far longer and broader use in companion-animal practice, while pregabalin remains the smaller, newer actor in the veterinary space. ## Snapshot, cumulativeness, and the "reported ≠ causal" rule These counts are **cumulative** as of the openFDA pull dated 2026-07-21 / 2026-07-22. They are not annual rates and they are not incidence proportions; they are the running tally of reports lodged in the FDA CVM database up to that snapshot. **Explicit disclaimer:** ADE reports are submitted by veterinarians, pet owners, manufacturers, and others. A report means a reaction was *observed and recorded*, not that the drug *caused* it. The source topics themselves state the figures "do not imply causation." Correlation between a drug and a reported event is not evidence of a causal link. Anyone reading "10,445 gabapentin reports" as "gabapentin caused harm in 10,445 animals" is misreading the data. A second, easily-missed point lives in the reaction terms. Under VEDDRA (the veterinary dictionary for drug-related adverse events), **"Lack of efficacy" terms denote product-performance reports, not adverse reactions.** Both topics surface lack-of-efficacy entries — for gabapentin, "Lack of efficacy - NOS 877"; for pregabalin, "Lack of efficacy - NOS 42". These are reports that the product did not work as expected, not that the animal was harmed. They must not be lumped into a "side-effect" tally. ## Species breakdown Who are these reports about? The species splits are striking and tell their own story. Gabapentin reports by species (top entries): - Dog 8575 - Cat 1836 - Human 17 - Horse 3 - Ferret 2 - Goat 2 Pregabalin reports by species (top entries): - Cat 127 - Dog 61 - Human 4 Two things stand out. First, dogs dominate the gabapentin record (8,575 of 10,445, or about 82%), with cats a distant second — the mirror of how gabapentin is most often reached for in canine pain and seizure management. Second, the human entries (17 for gabapentin, 4 for pregabalin) are a reminder that this is an open reporting system: accidental exposure, household cross-contact, or a human reporter can land a human case in an animal database. They are not veterinary patients. Pregabalin's species order is the reverse of gabapentin's at the top — Cat 127 ahead of Dog 61 — though the absolute numbers are small enough that this ordering should be read with caution rather than as a strong clinical signal. ## Reaction profile The top reported reactions (VEDDRA terms) differ in emphasis between the two drugs. For pregabalin, the leading entries are: - Lack of efficacy - NOS 42 - Lethargy (see also Central nervous system depression in Neurological) 31 - Ataxia 24 - Death by euthanasia 18 - Vomiting 17 - Overdose 16 - Wobbliness 15 - Medication error NOS 13 - Seizure NOS 13 - Intentional misuse 11 For gabapentin, the leading entries are: - Vomiting 1597 - Diarrhoea 1170 - Death by euthanasia 1157 - Lethargy (see also Central nervous system depression in Neurological) 1113 - Not eating 916 - Lack of efficacy - NOS 877 - Decreased appetite 688 - Elevated alanine aminotransferase (ALT) 673 - Ataxia 641 - Lethargy (see also Central nervous system depression in 'Neurological') 634 Both profiles are dominated by the classic gabapentinoid signature: sedation and ataxia (wobbliness, lethargy, "Central nervous system depression"), plus gastrointestinal signs (vomiting, diarrhoea, not eating, decreased appetite). That pattern is exactly what clinicians expect from this drug class — the reports largely corroborate the known adverse-effect profile rather than surfacing surprises. Two entries deserve a careful read. "Death by euthanasia" appears high on both lists (gabapentin 1157; pregabalin 18). This is a reported outcome, frequently recorded when a severely ill animal is euthanised; it is not, by itself, evidence the drug was fatal. And "Overdose 16" plus "Intentional misuse 11" and "Medication error NOS 13" in the pregabalin topic point to a human-side problem — gabapentinoids are controlled-substance-adjacent in people, and misuse, accidental overdose, and dosing errors show up in the veterinary record too. "Elevated alanine aminotransferase (ALT) 673" in the gabapentin topic is the one liver-enzyme signal worth a clinician's eye, but as with every entry here, a report is an observation, not a proven hepatic injury attributed to the drug. ## The China half: pending, not invented The original brief asked for a contrast with China's Ministry of Agriculture and Rural Affairs (MOA) new-veterinary-drug announcements — Announcement 1022 and Announcement 1038 — and for the Chinese drug name to be written alongside the INN whenever a China source was cited (for example, the CN rendering of pregabalin/gabapentin as it appears in Ann 1038, plus the INN). The corresponding source topics (`cn_moa_ann1022_new_veterinary_drugs_pet`, `cn_moa_ann1038_new_veterinary_drugs_pet`) were **not present on disk** at writing time, and neither was the FDA Green Book topic (`fda_green_book_recent_approvals_pet_drug_2024_2026`). Because this project forbids substituting second-hand text or agent-written summaries for first-hand source documents, the China MOA contrast and the CN/INN dual-naming requirement **cannot be satisfied here without fabrication** — and fabrication is explicitly prohibited. The China side is therefore left pending. When the Ann 1022 / Ann 1038 topics are collected and verified on disk, the dual-named China section can be written against them, and the frontmatter `source_topics` updated to reflect the topics actually used. Until then, no Chinese drug name or approval figure is asserted in this article. ## What the US data does and does not tell us Taken together, the two FDA topics give a clear, first-hand view of how gabapentin and pregabalin behave in the real-world US veterinary record: gabapentin is the workhorse with a deep, sedation-and-GI-dominated report profile; pregabalin is the smaller, newer entrant. Both confirm the expected gabapentinoid signature. Neither tells us anything about causation, and both contain lack-of-efficacy entries that are not adverse reactions at all. The honest limit of this article is also its strength: every number above is a verbatim substring of a first-hand FDA source, the snapshot date is stated, and the "reported ≠ causal" boundary is drawn explicitly. The China contrast will have to earn its place the same way — from sources on disk, not from assumption. ## Sources Every figure and quoted phrase above is a verbatim substring of one of the following source topics (all confirmed present on disk). Caliber: **first-hand FDA CVM adverse-event data** (openFDA `animalandveterinary/event.json`), C1-verified by substring match in the topic files. - `ade_gabapentin_adverse_events` — Gabapentin: 10445 total; species Dog 8575 / Cat 1836 / Human 17 / Horse 3 / Ferret 2 / Goat 2; top reactions Vomiting 1597, Diarrhoea 1170, Death by euthanasia 1157, Lethargy 1113, Not eating 916, Lack of efficacy - NOS 877, Decreased appetite 688, Elevated ALT 673, Ataxia 641; pulled 2026-07-21 (identical total in a 2026-07-22 pull). First-hand FDA openFDA ADE; "Lack of efficacy terms denote product-performance reports, not adverse reactions." - `ade_pregabalin_adverse_events` — Pregabalin: 207 total; species Cat 127 / Dog 61 / Human 4; top reactions Lack of efficacy - NOS 42, Lethargy 31, Ataxia 24, Death by euthanasia 18, Vomiting 17, Overdose 16, Wobbliness 15, Medication error NOS 13, Seizure NOS 13, Intentional misuse 11; pulled 2026-07-22. First-hand FDA openFDA ADE. **Topics named in the brief but absent on disk — not used, not fabricated:** - `cn_moa_ann1022_new_veterinary_drugs_pet` — not found on disk; China MOA Ann 1022 contrast pending. - `cn_moa_ann1038_new_veterinary_drugs_pet` — not found on disk; China MOA Ann 1038 contrast and CN/INN dual naming pending. - `fda_green_book_recent_approvals_pet_drug_2024_2026` — not found on disk; not used.